Johnson & Johnson Taps Emergent BioSolutions to Help Manufacture Its COVID-19 Vaccine
Johnson & Johnson Taps Emergent BioSolutions to Help Manufacture Its COVID-19 Vaccine 1Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007. Follow @BiologyFool Johnson & Johnson (NYSE:JNJ) signed a contract to pay Emergent BioSolutions (NYSE:EBS) $135 million to help manufacture its vaccine to treat COVID-19, the disease caused by the …
News story posted on 2020-04-24T05:37:00.0000000Z